Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 48.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.04M |
| Shares Out | 4.04M |
| EPS (ttm) | -3.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,345 |
| Open | 10.62 |
| Previous Close | 11.75 |
| Day's Range | 10.11 - 12.91 |
| 52-Week Range | n/a |
| Beta | -167,970.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2023 |
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,... [Read more]
Financial Performance
Financial StatementsNews
Eloxx Pharmaceuticals Inc trading resumes
14:24 EDT Eloxx Pharmaceuticals (ELOX) Inc trading resumes
Eloxx Pharmaceuticals Inc trading halted, volatility trading pause
14:19 EDT Eloxx Pharmaceuticals (ELOX) Inc trading halted, volatility trading pause
Eloxx Pharmaceuticals Inc trading halted, volatility trading pause
09:30 EDT Eloxx Pharmaceuticals (ELOX) Inc trading halted, volatility trading pause
Eloxx Pharmaceuticals Inc trading resumes
09:40 EDT Eloxx Pharmaceuticals (ELOX) Inc trading resumes
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule produ...
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Quarterly report: Q1 2026
Eloxx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Eloxx Pharmaceuticals Annual report: Q4 2025
Eloxx Pharmaceuticals has published its Q4 2025 annual report on March 17, 2026.
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
Eloxx Pharmaceuticals provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation for ELX-02. ELX-02: Regulatory and Clinical Updates for Alport Syndrome Nonsense Mutation Progr...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Eloxx Pharmaceuticals’ treatment of Alport Syndrome was granted orphan status by the FDA, according to a post to the agency’s website.
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an e...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agr...
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on January 25, 2024, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
06:12 EST Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome
Eloxx Pharmaceuticals Quarterly report: Q3 2023
Eloxx Pharmaceuticals has published its Q3 2023 quarterly earnings report on November 13, 2023.
Eloxx Pharmaceuticals Earnings release: Q3 2023
Eloxx Pharmaceuticals released its Q3 2023 earnings on November 13, 2023, summarizing the period's financial results.
Eloxx Pharmaceuticals price target lowered to $30 from $60 at Oppenheimer
Oppenheimer lowered the firm’s price target on Eloxx Pharmaceuticals to $30 from $60 due to the continuing market compression in biotech stocks, while keeping an Outperform rating on the shares.
Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA
Eloxx Pharmaceuticals reported results from an assessment of patient biopsies by NIPOKA GmbH. They have developed a highly accurate method for the quantification of podocyte foot process morphology. T...
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has ent...